The short version of MC4R fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-06-17 and is reviewed periodically as new material appears.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic melanocortin analogue |
| Molecular formula | C50H68N14O10 | Corresponds to a mass near 1025 daltons |
| Appearance | White to off-white powder | Lyophilised solid before reconstitution |
| Solubility | Soluble in water and polar solvents | Poor solubility in nonpolar media |
| Common synonyms | Bremelanotide, PT-141 | Code name and international name used interchangeably |
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
=== Nobel Prizes for vitamin research === The Nobel Prize for Chemistry for 1928 was awarded to Adolf Windaus "for his studies on the constitution of the sterols and their connection with vitamins", the first person to receive an award mentioning vitamins, even though it was not specifically about vitamin D. The Nobel Prize in Physiology or Medicine for 1929 was awarded to Christiaan Eijkman and Frederick Gowland Hopkins for their contributions to the discovery of vitamins. Thirty-five years earlier, Eijkman had observed that chickens fed polished white rice developed neurological symptoms similar to those observed in military sailors and soldiers fed a rice-based diet, and that the symptoms were reversed when the chickens were switched to whole-grain rice. He called this "the anti-beriberi factor", which was later identified as vitamin B1, thiamine. In 1930, Paul Karrer elucidated the correct structure for beta-carotene, the main precursor of vitamin A, and identified other carotenoids. Karrer and Norman Haworth confirmed Albert Szent-Györgyi's discovery of ascorbic acid and made significant contributions to the chemistry of flavins, which led to the identification of lactoflavin. For their investigations on carotenoids, flavins and vitamins A and B2, they both received the Nobel Prize in Chemistry in 1937. In 1931, Albert Szent-Györgyi and a fellow researcher Joseph Svirbely suspected that "hexuronic acid" was actually vitamin C, and gave a sample to Charles Glen King, who proved its ability to counter scurvy in his long-established guinea pig scorbutic assay.
Austin held on to the WWF Championship until SummerSlam on August 22 when he lost it to Mankind in a triple threat match also featuring Triple H. in the two months that followed, Triple H would gain possession of the title. Austin would get his rematch at No Mercy on October 17 against Triple H, but Austin lost after The Rock accidentally struck him with a sledgehammer shot meant for Triple H. The three were advertised for a triple-threat match at Survivor Series on November 14, where Austin was run down by a car. The segment was to write him off television, with the neck injury suffered two years prior posing a real threat of early retirement, and was advised to undergo surgery. Austin would later describe this as "the worst storyline I was ever involved in". Austin made a one-off appearance at Backlash on April 30, 2000, attacking Triple H and Vince McMahon to help The Rock reclaim the WWF Championship. After Austin's official return at Unforgiven on September 24, Commissioner Mick Foley led an investigation to find out who ran Austin over, with the culprit revealed to be Rikishi. At No Mercy on October 22, Austin faced Rikishi in a No Holds Barred match, during which Austin attempted to run Rikishi down in a truck, but was prevented from doing so by officials, and the match was deemed a no contest; Austin was subsequently arrested. During a handicap match against Rikishi and Kurt Angle, Triple H came down with the apparent intention of teaming with Austin, only to hit Austin with a sledgehammer and reveal he had instructed Rikishi to run him over.
==== The locus of power and organized crime ==== Some espouse that all organized crime operates at an international level, though there is currently no international court capable of trying offenses resulting from such activities (the International Criminal Court's remit extends only to dealing with people accused of offenses against humanity, e.g., genocide). If a network operates primarily from one jurisdiction and carries out its illicit operations there and in some other jurisdictions it is 'international,' though it may be appropriate to use the term 'transnational' only to label the activities of a major crime group that is centered in no one jurisdiction but operating in many. The understanding of organized crime has therefore progressed to combined internationalization and an understanding of social conflict into one of power, control, efficiency risk and utility, all within the context of organizational theory. The accumulation of social, economic and political power have sustained themselves as a core concerns of all criminal organizations:
== Examples == Typical bacteria are 1 to 10 μm in diameter. Human hair typically varies in diameter from 17 to 181 μm. Eukaryotic cells are typically 10 to 100 μm in diameter. Capacitance values of electrolytic capacitors in everyday electronics typically range from 1 to 47,000 μF
=== Other applications === One of the most desirable uses for protein design is for biosensors, proteins that will sense the presence of specific compounds. Some attempts in the design of biosensors include sensors for unnatural molecules including TNT. More recently, Kuhlman and coworkers designed a biosensor of the PAK1. In a sense, protein design is a subset of battery design.
Sources: en.wikipedia.org
== Adverse effects == Citalopram theoretically causes side effects by increasing the concentration of serotonin in other parts of the body (e.g., the intestines). Other side effects, such as increased apathy and emotional flattening, may be caused by the decrease in dopamine release associated with increased serotonin. Citalopram is also a mild antihistamine, which may be responsible for some of its sedating properties. Other common side effects of citalopram include drowsiness, insomnia, nausea, weight changes (usually weight gain), increase in appetite, vivid dreaming, frequent urination, dry mouth, increased sweating, trembling, diarrhea, excessive yawning, severe tinnitus, and fatigue. Less common side effects include bruxism, vomiting, cardiac arrhythmia, blood pressure changes, dilated pupils, anxiety, mood swings, headache, hyperactivity and dizziness. Rare side effects include convulsions, hallucinations, severe allergic reactions and photosensitivity. If sedation occurs, the dose may be taken at bedtime rather than in the morning. Some data suggest citalopram may cause nightmares. Citalopram is associated with a higher risk of arrhythmia than other SSRIs. Citalopram and other SSRIs can induce a mixed state, especially in those with undiagnosed bipolar disorder.
IMA Life (previously known as IMA Edwards, Libra and BOC Edwards Pharmaceutical Systems) is one of the few companies which are prominent in the manufacturing of freeze dryers especially for the pharmaceutical and biotechnological companies, aseptic processing and filling solutions. It was previously owned by the BOC Group and then the Linde Group until recently when it was bought by the IMA Group based in Italy.
Acetyl-CoA is generated in the mitochondria from pyruvate molecules derived from glucose via glycolysis. Within the mitochondria, acetyl-CoA typically combines with oxaloacetate and serves as a substrate for the synthesis of citrate as part of the well known citric acid cycle. Notably, the inner mitochondrial membrane is impermeable to acetyl-CoA, and as such, a specialized shuttle system must be used to import acetyl-CoA into the cytosol for fatty acid production. This process, known as the citrate–malate shuttle, relies on the tricarboxylate transport protein to import citrate into the cytosol, where it is then split into acetyl-CoA and oxaloacetate by the enzyme ATP citrate lyase (ACL). Cytosolic acetyl-CoA is then available for use in fatty acid and cholesterol synthesis, but oxaloacetate must be reduced to malate in order to reenter the mitochondria. Malate dehydrogenase reduces cytosolic oxaloacetate by coupling NADH oxidation to NAD+, and malate produced by this reaction can be transported back into the mitochondria, thus completing the namesake of the citrate–malate shuttle.
=== Orthologs === C3orf52 retains its sequence with identifiable orthologs exclusively within vertebrates (see Table 1 below), specifically up to the elasmobranchii lineage, but is absent in more distantly related groups. Outside of vertebrates, including all invertebrate animals, bacteria, archaea, fungi, plants, and protists, no identifiable sequence homology is detected for this protein. The most distant homolog detected of C3orf52 was in the elephant shark (Callorhinchus milli), which diverged about 495.2 million years before humans, suggesting that this is approximately when the C3orf52 gene first arose.
The botched embalming of Pope Pius XII (1876–1958; pope 1939–1958) by a charlatan doctor – which only sped up the rate of decomposition – led to his body turning black and his nose falling off while lying in state, and the body disintegrated in the coffin. The Swiss Guards stationed around Pius XII's body were forced to change shifts every 10 to 15 minutes, since the body's odor caused some guards to pass out. The doctor who performed the embalming had also taken photos of the pontiff in his death throes, intending to sell them to tabloids. The Italian tabloids refused to buy the photos, and the doctor was banned from entering the Vatican City-State by John XXIII, who furthermore prohibited any photography of a deceased pope until the body is properly vested and laid out. Charles XII (1682–1718) is one of several Swedish kings to have been embalmed. When Charles XII's sarcophagus was opened in 1917, his features were still recognizable, almost 200 years after his death. Photographs of his remains clearly show the gunshot wound to his head leading to his death. The body of Pope John XXIII (1881–1963; pope 1958–1963) is on display on an altar on the main floor of the Basilica of Saint Peter after having been exhumed from the grottoes beneath the main altar and has retained an extremely well-preserved state. If a body's remains do not decompose, contrary to expectations, it is often treated as a miracle. However, the case of John XXIII's body did not enjoy the same acclamation, as it was held to have been due to embalming and adipocere formation.
Sources: en.wikipedia.org
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.
It is neither a steroid nor a naturally occurring human hormone. Bremelanotide is a manufactured peptide that mimics part of the melanocortin signalling system by binding receptor proteins. Its effects come from receptor activation, not from replacing a circulating hormone.
The internal lactam bridge locks the peptide into a defined shape, which raises receptor affinity and slows enzymatic breakdown. Linear versions of the same sequence are less stable and bind more weakly. Ring geometry is therefore central to how the molecule behaves in the body.
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.